JP2024523838A - Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 - Google Patents
Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 Download PDFInfo
- Publication number
- JP2024523838A JP2024523838A JP2023575788A JP2023575788A JP2024523838A JP 2024523838 A JP2024523838 A JP 2024523838A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2024523838 A JP2024523838 A JP 2024523838A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/099228 | 2021-06-09 | ||
| CN2021099228 | 2021-06-09 | ||
| PCT/CN2022/097889 WO2022258015A1 (en) | 2021-06-09 | 2022-06-09 | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523838A true JP2024523838A (ja) | 2024-07-02 |
| JP2024523838A5 JP2024523838A5 (cg-RX-API-DMAC7.html) | 2025-06-18 |
Family
ID=84425689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575788A Pending JP2024523838A (ja) | 2021-06-09 | 2022-06-09 | Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250282881A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4352108A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523838A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019797A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529503A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022288037A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221866A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308918A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202315893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022258015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017506215A (ja) * | 2013-12-30 | 2017-03-02 | エピムアブ バイオセラピューティクス インコーポレイテ | タンデム型Fab免疫グロブリン及びその使用 |
| JP2020514277A (ja) * | 2016-12-23 | 2020-05-21 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | プログラム死リガンド−1(pd−l1)に結合する抗体を使用する免疫 |
| US20200231692A1 (en) * | 2019-01-23 | 2020-07-23 | Beijing Mabworks Biotech Co. Ltd | Anti-ox40 antibodies and uses thereof |
| WO2020151761A1 (zh) * | 2019-01-25 | 2020-07-30 | 信达生物制药(苏州)有限公司 | 结合pd-l1和ox40的双特异性抗体 |
| EP3778648A1 (en) * | 2018-03-27 | 2021-02-17 | Innovent Biologics (Suzhou) Co., Ltd. | Novel antibody molecule, and preparation method and use thereof |
| JP2021509258A (ja) * | 2017-12-29 | 2021-03-25 | エーピー バイオサイエンスィズ インコーポレイテッド | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 |
| WO2021104434A1 (en) * | 2019-11-27 | 2021-06-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| CN111315405A (zh) * | 2017-11-09 | 2020-06-19 | 免疫医疗有限责任公司 | 双特异性融合多肽及其使用方法 |
| JP2021529557A (ja) * | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. | 抗腫瘍免疫チェックポイント調節因子アンタゴニスト |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| CN110003338B (zh) * | 2019-04-16 | 2021-04-23 | 北京免疫方舟医药科技有限公司 | 抗ox40抗体及其应用 |
-
2022
- 2022-06-09 EP EP22819612.7A patent/EP4352108A4/en active Pending
- 2022-06-09 WO PCT/CN2022/097889 patent/WO2022258015A1/en not_active Ceased
- 2022-06-09 AU AU2022288037A patent/AU2022288037A1/en active Pending
- 2022-06-09 IL IL308918A patent/IL308918A/en unknown
- 2022-06-09 TW TW111121529A patent/TW202315893A/zh unknown
- 2022-06-09 CA CA3221866A patent/CA3221866A1/en active Pending
- 2022-06-09 US US18/568,252 patent/US20250282881A1/en active Pending
- 2022-06-09 CN CN202280040981.5A patent/CN117529503A/zh active Pending
- 2022-06-09 KR KR1020247000219A patent/KR20240019797A/ko active Pending
- 2022-06-09 JP JP2023575788A patent/JP2024523838A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017506215A (ja) * | 2013-12-30 | 2017-03-02 | エピムアブ バイオセラピューティクス インコーポレイテ | タンデム型Fab免疫グロブリン及びその使用 |
| JP2020514277A (ja) * | 2016-12-23 | 2020-05-21 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | プログラム死リガンド−1(pd−l1)に結合する抗体を使用する免疫 |
| JP2021509258A (ja) * | 2017-12-29 | 2021-03-25 | エーピー バイオサイエンスィズ インコーポレイテッド | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 |
| EP3778648A1 (en) * | 2018-03-27 | 2021-02-17 | Innovent Biologics (Suzhou) Co., Ltd. | Novel antibody molecule, and preparation method and use thereof |
| US20200231692A1 (en) * | 2019-01-23 | 2020-07-23 | Beijing Mabworks Biotech Co. Ltd | Anti-ox40 antibodies and uses thereof |
| WO2020151761A1 (zh) * | 2019-01-25 | 2020-07-30 | 信达生物制药(苏州)有限公司 | 结合pd-l1和ox40的双特异性抗体 |
| WO2021104434A1 (en) * | 2019-11-27 | 2021-06-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS |
Non-Patent Citations (3)
| Title |
|---|
| BINGLIANG CHEN ET AL.: "The PD-L1 and OX40 bispecific antibody IBI327 induces immune activation and improves cancer immunoth", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 2020, vol. vol.80(16 Suppl), JPN6026015106, 22 June 2020 (2020-06-22), pages 2268, ISSN: 0005847144 * |
| KUANG Z.: "A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment", MOL CANCER THER, vol. vol.19(12), JPN6026015105, December 2020 (2020-12-01), pages 2564 - 2574, ISSN: 0005847146 * |
| MICHAEL D. ET AL.: "A novel immunostimulatory OX40/PD-L1 bivalent bispecific antibody (MEDI1109) for the treatment of pa", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2018, vol. vol.78(13 Suppl), JPN6026015104, 14 April 2018 (2018-04-14), pages 2775, ISSN: 0005847145 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117529503A (zh) | 2024-02-06 |
| EP4352108A4 (en) | 2026-01-07 |
| IL308918A (en) | 2024-01-01 |
| KR20240019797A (ko) | 2024-02-14 |
| AU2022288037A9 (en) | 2024-01-04 |
| TW202315893A (zh) | 2023-04-16 |
| CA3221866A1 (en) | 2022-12-15 |
| WO2022258015A1 (en) | 2022-12-15 |
| EP4352108A1 (en) | 2024-04-17 |
| US20250282881A1 (en) | 2025-09-11 |
| AU2022288037A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7847630B2 (ja) | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 | |
| TWI907489B (zh) | 抗ror1抗體及相關雙特異性結合蛋白 | |
| TWI793129B (zh) | 細胞毒性t淋巴球相關蛋白4 (ctla-4) 之新穎單株抗體 | |
| TW202302636A (zh) | 靶向bcma、gprc5d及cd3之三特異性抗體 | |
| US12060425B2 (en) | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom | |
| CN108948194B (zh) | 一种新的ctla-4单克隆抗体 | |
| WO2022258015A1 (en) | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 | |
| TWI772984B (zh) | TGFβ/PD-L1雙特異性結合蛋白 | |
| TW202035448A (zh) | 有效表現之egfr及pd-l1雙特異性結合蛋白 | |
| US20240317862A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof | |
| TWI835166B (zh) | 靶向pd-1和/或ox40的特異性結合蛋白及其應用 | |
| TWI833227B (zh) | 靶向pd-l1和cd73的特異性結合蛋白及其應用 | |
| RU2852663C1 (ru) | Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них | |
| RU2782381C2 (ru) | Высокоаффинные анти-pd-1 и анти-lag-3 антитела и полученные из них биспецифические связывающие белки | |
| TW202544031A (zh) | 抗tigit/抗pd-l1雙特異性抗體及其用途 | |
| HK40067877A (en) | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240229 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20240229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260722 |